Trv Gp Vi LLC Takes Position in Rapport Therapeutics (NASDAQ:RAPP)

TRV GP VI LLC acquired a new stake in Rapport Therapeutics (NASDAQ:RAPP - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 969,218 shares of the company's stock, valued at approximately $17,194,000. Rapport Therapeutics comprises approximately 14.7% of TRV GP VI LLC's investment portfolio, making the stock its 3rd biggest position. TRV GP VI LLC owned about 2.65% of Rapport Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC bought a new stake in Rapport Therapeutics during the 3rd quarter worth approximately $4,133,000. State Street Corp acquired a new position in Rapport Therapeutics during the 3rd quarter worth approximately $1,189,000. Jennison Associates LLC acquired a new position in shares of Rapport Therapeutics during the 4th quarter worth about $1,105,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Rapport Therapeutics in the fourth quarter valued at about $34,000. Finally, Barclays PLC raised its stake in shares of Rapport Therapeutics by 36.8% during the 3rd quarter. Barclays PLC now owns 12,863 shares of the company's stock worth $264,000 after purchasing an additional 3,463 shares in the last quarter.

Insider Transactions at Rapport Therapeutics

In related news, Director Wendy B. Young purchased 6,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were bought at an average cost of $10.21 per share, with a total value of $61,260.00. Following the acquisition, the director now owns 6,000 shares of the company's stock, valued at $61,260. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Troy A. Ignelzi purchased 9,900 shares of the stock in a transaction dated Wednesday, March 12th. The shares were bought at an average price of $10.10 per share, with a total value of $99,990.00. Following the completion of the acquisition, the chief financial officer now directly owns 9,900 shares of the company's stock, valued at approximately $99,990. This represents a ∞ increase in their position. The disclosure for this purchase can be found here.

Rapport Therapeutics Price Performance

RAPP traded down $0.17 during trading on Wednesday, hitting $11.38. 176,162 shares of the stock traded hands, compared to its average volume of 178,169. The business has a 50 day moving average price of $10.30 and a 200 day moving average price of $16.63. The company has a market cap of $415.32 million and a price-to-earnings ratio of -0.82. Rapport Therapeutics has a twelve month low of $6.43 and a twelve month high of $29.74.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Citizens Jmp initiated coverage on shares of Rapport Therapeutics in a report on Tuesday, April 8th. They issued a "mkt outperform" rating on the stock. JMP Securities started coverage on shares of Rapport Therapeutics in a research report on Tuesday, April 8th. They issued a "market outperform" rating and a $28.00 price target for the company. Four research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Rapport Therapeutics has a consensus rating of "Buy" and an average price target of $32.67.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.